Novavax Scores Another Nod For Its COVID-19 Shot In Adolescents
The Medicines and Healthcare products Regulatory Agency in the U.K. has granted expanded conditional approval for Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine, Nuvaxovid…
Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have completed a submission to the European Medicines Agency (EMA) for a booster dose of an…
2 Fintech Dividend Stocks For A Secure Cash Flow
As of the past few months, numerous fintech startups have been suffering the brunt of the bear market, as layoffs in the technology industry have led the way.
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has
Merck’s Buyout Of Seagen Hits Speed Braker Over Price Agreement: Report
Merck & Co Inc (NYSE:MRK) and Seagen Inc (NASDAQ:SGEN) have not been able to agree on a buyout price, Bloomberg reported. The…
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).
Pfizer’s COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows
According to a new observational study published in the New England Journal of Medicine, Pfizer Inc's (NYSE: PFE) COVID-19 treatment, Paxlovid, only worked among patients 65 years of age or older, with
With Sandoz Spinoff, Novartis Slams Brakes On Huntington’s Trial
Novartis AG (NYSE: NVS) suspended dosing in a Huntington's disease study because early signs of side effects were seen in some participants in the trial.
Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments
The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ:AZN) and Merck Co Inc’s (NYSE:MRK) Lynparza (olaparib) for the adjuvant treatment of patients with…
AstraZeneca’s CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ: